Physical and spectroscopic data of saponins 510 Table 1S . On the basis of its spectra compared with literature data and by acid hydrolysis followed by GC analysis of the corresponding trimethylsilylated monosaccharides, saponin 5 was identified as leontoside, i.e., Table 1S .
3-O--D-glucopyranosyl-(1→4)--L-arabinopyranosyl hederagenin
On the basis of its spectra compared with literature data and by acid hydrolysis followed by GC analysis of the corresponding trimethylsilylated monosaccharides, saponin 6 was identified as cauloside D, i.e., Table 1S . On the basis of its spectra compared with literature data and by acid hydrolysis followed by GC analysis of the corresponding trimethylsilylated monosaccharides, saponin 7 was identified as kizutasaponin Table 1S . On the basis of its spectra compared with literature data and by acid hydrolysis followed by GC analysis of the corresponding trimethylsilylated monosaccharides, saponin 8 was identified as clematibetoside C, i.e., Hz Table 1S . On the basis of its spectra compared with literature data and by acid hydrolysis followed by GC analysis of the corresponding trimethylsilylated monosaccharides, saponin 9 was identified as hederacholichiside F, i.e., Table 1S . On the basis of its spectra compared with literature data and by acid hydrolysis followed by GC analysis of the corresponding trimethylsilylated monosaccharides, saponin 10 was identified as asperosaponin VI, i.e., 
Description of bioassay
The anti-ischemic activities of saponins 1−10 were evaluated by the serum levels of LDH and CK-MB in hypoxia treated cardiomyocytes, with diltiazem hydrochloride injection (10 mg/vial, >98%; Tanabe Seiyaku
Co., Ltd.) as positive control. The myocardial cells were grown in culture medium supplemented with 100 U/mL penicillin and 0.1 mg/mL streptomycin. Cells were harvested at the log phase of growth, and then seeded into 96-well plates (100 μL/well at a density of 5 × 10 5 cells/mL). After 3 h incubation at 37°C and 5% CO 2 to allow cell attachment, control or various concentrations of test solution was put into each well, and the plates were incubated for an additional 24 h. Subsequently, cells were put in a little hypoxia box (95% N 2 + 5% CO 2 were charged into the box at 1 L/min flow continuously, oxygen concentration <0.1%, 37°C) and incubated for 3 h [7] . The cardioprotective activities of compounds 110 and diltiazem were determined at 160, 80, 40, 20, 10, and 5 M (each concentration was tested in triplex wells), respectively.
The CK−MB and LDH levels were determined spectrophotometrically at 660 nm and 340 nm, respectively, using diagnostic kits (Jiancheng Co., Ltd.), according to the manufacturer's instructions. Data were calculated as the relative LDH (CK-MB) release rate by the formula:
% LDH (CK-MB) release = [(Test Sample -Control)/(Model -Control)] 100%
Test Sample: cells were pretreated with saponins and then subjected to hypoxia condition for 3 h;
Control: cells were incubated normal condition;
Model: cells were incubated hypoxia condition for 3 h.
The ED 50 values were calculated with the software Origin 7.5 G (OriginLab Inc., USA) using the logistic function.
